Truist analyst David MacDonald raised the firm’s price target on Labcorp (LH) to $290 from $274 and keeps a Buy rating on the shares as part of a broader research note on Health Care Services. The firm is updating its models to reflect Q1 results and updated guidance on select names, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Labcorp Holdings to Webcast Annual Shareholder Meeting
- Labcorp price target raised to $280 from $260 at Piper Sandler
- Positive Outlook for Labcorp Holdings: Buy Rating Affirmed Amid Solid Growth and Strategic Moves
- Labcorp price target raised to $267 from $253 at Baird
- Labcorp price target raised to $250 from $240 at Barclays